Hemostemix Inc. (HEM.V)
| Previous Close | 0.1600 |
| Open | 0.1600 |
| Bid | 0.1600 x 0 |
| Ask | 0.1650 x 0 |
| Day's Range | 0.1600 - 0.1600 |
| 52 Week Range | 0.1150 - 0.4200 |
| Volume | |
| Avg. Volume | 84,108 |
| Market Cap | 9.464M |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2410 |
| Earnings Date | Sept 26, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.96 |
- Newsfile
Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview
Calgary, Alberta--(Newsfile Corp. - November 17, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to thank six-time Grammy Award Winner, Mr. Howie Lindeman, for his ACP-01 testimonial interview (https://www.youtube.com/watch?v=KTuq3Oy7WU0) now available on YouTube.Cannot view this video? Visit:https://www.youtube.com/watch?v=KTuq3Oy7WU0Mr. Howard "Howie" Lindeman started at The Record Plant recording studios NYC in 1974. His career as a Pr
- Newsfile
Hemostemix Announces Advancements in Its Automation of Production
Calgary, Alberta--(Newsfile Corp. - November 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the continued evolution of its patented Automated Cell Therapy System (ACTS). The Hemostemix ACTS is designed to scale our autologous stem cell therapy processes by leveraging robotic-material-handling and parallel-processing efficiencies, duplicating our manual methods of angiogenic cell precursor (ACP-01) production. ACTS will sc
- Newsfile
Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials
Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Medicine and Clinical Trials. Dr. Giannetti and Dr. Cecere will assist Hemostemix with financing introductions and due diligence responses; help position ACP-01 as a candidate to be the first-to-patient autologous stem cell treatment of heart disease; design
